Wedbush Reaffirms Outperform Rating for Aerovate Therapeutics (NASDAQ:AVTE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Tuesday, Benzinga reports. They currently have a $41.00 target price on the stock. Wedbush’s target price points to a potential upside of 95.15% from the stock’s current price. Wedbush also issued estimates […]
More Stories
Virginia National Bankshares Co. (NASDAQ:VABK) Short Interest Up 31.7% in December
Virginia National Bankshares Co. (NASDAQ:VABK – Get Free Report) saw a large increase in short interest in December. As of...
Gaming Realms (LON:GMR) Shares Pass Below 50 Day Moving Average – Here’s Why
Gaming Realms plc (LON:GMR – Get Free Report) shares passed below its fifty day moving average during trading on Friday...
Volcon, Inc. (NASDAQ:VLCN) Short Interest Update
Volcon, Inc. (NASDAQ:VLCN – Get Free Report) was the target of a significant drop in short interest in the month...
Vanguard Intermediate-Term Treasury Index ETF (NASDAQ:VGIT) Short Interest Update
Vanguard Intermediate-Term Treasury Index ETF (NASDAQ:VGIT – Get Free Report) was the recipient of a large decrease in short interest...
Canlan Ice Sports Corp. (ICE) to Issue Quarterly Dividend of $0.03 on January 15th
Canlan Ice Sports Corp. (TSE:ICE – Get Free Report) announced a quarterly dividend on Tuesday, December 31st,TickerTech Dividends reports. Investors...
TotalEnergies SE (TTE) To Go Ex-Dividend on December 31st
TotalEnergies SE (NYSE:TTE – Get Free Report) announced a dividend on Monday, November 25th,NASDAQ Dividends reports. Stockholders of record on...